You are here: Industry Insights > AZ

News List

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer pharmafile
June 07, 2018
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib) in combination with J&J’s standard-of-care drug Zytiga (abiraterone) in the tre
AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals pharmatimes
June 06, 2018
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival (rPFS) in prostate cancer patients taking a combination of Lynparza and abiraterone.
AZ lung cancer combo fails to hit targets pharmatimes
April 25, 2018
A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival.
AZ buys Ionis’ NASH candidate pharmatimes
April 11, 2018
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million.
US approves AZ/MSD’s Lynparza for breast cancer pharmatimes
January 16, 2018
US regulators have further expanded the scope of AstraZeneca and MSD’s Lynparza to include treatment of patients with BCRA-mutant metastatic breast cancer.
AZ's Fasenra approved in Europe as an add-on for severe eosinophilic asthma pharmafile
January 12, 2018
AstraZeneca and its Biologics R & D division, MedImmune, announced that their drug, Fasenra (benralizumab), has been approved by the European Commission (EC)
AZ partners with Combinations Alliance to test drug in cancer pharmafile
November 27, 2017
A clinical trial is to be launched to test AstraZeneca’s experimental drug, AZD1775, for the treatment of head and neck cancer in the UK.
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits fiercepharma
November 23, 2017
Last year, real-world data showed that SGLT2 diabetes drugs could significantly cut heart failure hospitalizations and all-cause deaths.
AZ’ experimental asthma drug fails in Phase III pharmatimes
November 03, 2017
An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.
AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide pharmafile
October 25, 2017
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 billion, with Roche coming out on top within the pharmaceutical industry with a total expenditure of $11.4 billion in 2017

Previous page 1 2 3 4 5 Next page